DE641443T1 - Quantitativer Gerinnungstest für aktievierten Faktor VII. - Google Patents

Quantitativer Gerinnungstest für aktievierten Faktor VII.

Info

Publication number
DE641443T1
DE641443T1 DE0641443T DE92917364T DE641443T1 DE 641443 T1 DE641443 T1 DE 641443T1 DE 0641443 T DE0641443 T DE 0641443T DE 92917364 T DE92917364 T DE 92917364T DE 641443 T1 DE641443 T1 DE 641443T1
Authority
DE
Germany
Prior art keywords
factor
assay
viia
factor viia
factor vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0641443T
Other languages
English (en)
Inventor
James Morrissey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of DE641443T1 publication Critical patent/DE641443T1/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/821—Chemistry: analytical and immunological testing involving complement factors or complement systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control
DE0641443T 1991-04-10 1992-04-09 Quantitativer Gerinnungstest für aktievierten Faktor VII. Pending DE641443T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/683,682 US5472850A (en) 1991-04-10 1991-04-10 Quantitative clotting assay for activated factor VII
PCT/US1992/002898 WO1992018870A1 (en) 1991-04-10 1992-04-09 Quantitative clotting assay for activated factor vii

Publications (1)

Publication Number Publication Date
DE641443T1 true DE641443T1 (de) 1995-10-12

Family

ID=24745031

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69230183T Expired - Lifetime DE69230183T2 (de) 1991-04-10 1992-04-09 Quantitativer gerinnungstest für aktivierten faktor vii
DE0641443T Pending DE641443T1 (de) 1991-04-10 1992-04-09 Quantitativer Gerinnungstest für aktievierten Faktor VII.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69230183T Expired - Lifetime DE69230183T2 (de) 1991-04-10 1992-04-09 Quantitativer gerinnungstest für aktivierten faktor vii

Country Status (10)

Country Link
US (3) US5472850A (de)
EP (1) EP0641443B1 (de)
JP (1) JP3047120B2 (de)
KR (1) KR940700679A (de)
AT (1) ATE185901T1 (de)
AU (1) AU663713B2 (de)
CA (1) CA2108282C (de)
DE (2) DE69230183T2 (de)
ES (1) ES2072243T3 (de)
WO (1) WO1992018870A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
DE69224622T2 (de) * 1991-10-04 1998-11-05 Dade Behring Inc Herstellung von prothrombinzeit-reagenzien aus rekombinantem menschlichem gewebefaktor und sythetischen phospholipiden
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1994007515A1 (en) * 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
US7169572B1 (en) * 1993-01-29 2007-01-30 T.A.C. Thrombosis And Coagulation Ab Assays for determining anticoagulant cofactor activity
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5766869A (en) * 1995-11-30 1998-06-16 Ahs Hospital Corp. Factor V ratio blood test for susceptibility to thromboembolism
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
CA2278106C (en) 1997-01-22 2005-04-12 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
DE19714559C1 (de) * 1997-04-09 1998-08-06 Blutspendedienst Der Drk Lande Verfahren zur Bestimmung von aktivierten Blutgerinnungsfaktoren in Plasma und Plasmaderivaten
EP0975975A1 (de) * 1997-04-09 2000-02-02 Blutspendedienst der DRK-Landesverbände Nordrhein und Westfalen-Lippe GmbH Verfahren zur bestimmung von aktivierten blutgerinnungsfaktoren in plasma und plasmaderivaten
US6100072A (en) * 1997-04-23 2000-08-08 Instrumentation Laboratory S.P.A. Recombinant rabbit tissue factor based prothrombin time reagent
DE19720853A1 (de) * 1997-05-17 1998-11-19 Dade Behring Marburg Gmbh Erhöhung der FVII Empfindlichkeit eines Thromboplastinreagenzes
US6245573B1 (en) 1998-02-12 2001-06-12 University Of Medicine And Dentistry Of New Jersey Rapid assessment of the coagulant activity of blood
KR100440044B1 (ko) * 1998-02-27 2004-07-14 팸진 비.브이. 핵산의 비특이적 증폭방법
WO1999049803A1 (en) * 1998-04-01 1999-10-07 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
EP1084270B1 (de) 1998-06-08 2004-08-25 The University Of Vermont And State Agricultural College Verfahren zur Bestimmung der Blutgerinnung in Plasma
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
GB2358862B (en) * 1999-12-21 2004-07-21 Fermentron Ltd Processes for Extracting Carotenoids from Biomass Carotenoid Sources
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6743596B1 (en) * 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US6855509B2 (en) * 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US7110118B2 (en) * 2000-12-19 2006-09-19 Trustees Of Boston University Spectral imaging for vertical sectioning
DE10064689B4 (de) * 2000-12-22 2004-08-05 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Verfahren zur Bestimmung der Blutzellhämostase
US6596543B2 (en) 2001-03-22 2003-07-22 Dade Behring Inc. Use of liposomes of defined composition and size for the preparation of prothrombin time reagents
EP1260817A3 (de) * 2001-05-08 2002-12-18 Warner-Lambert Company Methode zur Direktbestimmung von Koagulationsfaktor VIIa in Plasma
JP4584574B2 (ja) * 2001-07-03 2010-11-24 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン 第ＶＩＩａ因子−アンチトロンビン複合体を測定するためのアッセイ
US20030124132A1 (en) * 2001-09-27 2003-07-03 Board Of Regents, The University Of Texas System Combined compositions for tumor vasculature coaguligand treatment
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
ES2523655T5 (es) * 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
US7604932B2 (en) * 2002-11-13 2009-10-20 Haematologic Technologies, Inc. Assay for tissue factor in a sample
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1628677B1 (de) 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Stabilisierung von proteinen in lösung
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
EP1656158B1 (de) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Flüssige, wässrige pharmazeutische zusammensetzung von faktor-vii-polypeptiden
EP2311437A1 (de) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
US7148067B2 (en) * 2004-08-31 2006-12-12 The Board Of Trustees Of The University Of Illinois Thromboplastin reagents
US20080260858A1 (en) * 2005-02-16 2008-10-23 The Board Of Trustees Of The University Of Illnois Universal Procoagulant
EP1869082B1 (de) * 2005-03-04 2011-04-13 The Board Of Trustees Of The University Of Illinois Modulator von coagulationskaskaden und fibrinolytischen kaskaden
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
US8574849B2 (en) * 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
US8821861B2 (en) * 2007-10-05 2014-09-02 The Board Of Trustees Of The University Of Illinois Fibrin sealant
US20100297257A1 (en) * 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
DE102009048199A1 (de) * 2009-10-05 2011-04-21 Siemens Healthcare Diagnostics Products Gmbh Verfahren zur Bestimmung von Faktor XIII mit Hilfe von Referenzmaterial auf Plasmabasis
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
WO2017119508A1 (ja) * 2016-01-07 2017-07-13 藤森工業株式会社 採血管、試薬及びそれらを利用した血液性状分析方法
JP6626761B2 (ja) * 2016-03-30 2019-12-25 シスメックス株式会社 プロトロンビン時間測定用試薬およびその製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479938A (en) * 1981-06-25 1984-10-30 Baxter Travenol Laboratories, Inc. Therapeutic composition containing factor VIIa
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
ATE66374T1 (de) * 1985-11-26 1991-09-15 Novo Nordisk As Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

Also Published As

Publication number Publication date
ES2072243T3 (es) 2000-03-16
ES2072243T1 (es) 1995-07-16
ATE185901T1 (de) 1999-11-15
EP0641443B1 (de) 1999-10-20
US5472850A (en) 1995-12-05
CA2108282A1 (en) 1992-10-11
DE69230183D1 (de) 1999-11-25
EP0641443A1 (de) 1995-03-08
JPH06506601A (ja) 1994-07-28
US5741658A (en) 1998-04-21
US5750358A (en) 1998-05-12
AU1872992A (en) 1992-11-17
CA2108282C (en) 2003-09-09
WO1992018870A1 (en) 1992-10-29
KR940700679A (en) 1994-02-23
AU663713B2 (en) 1995-10-19
JP3047120B2 (ja) 2000-05-29
DE69230183T2 (de) 2000-08-31

Similar Documents

Publication Publication Date Title
DE641443T1 (de) Quantitativer Gerinnungstest für aktievierten Faktor VII.
Barrett Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates.
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
DK0420332T3 (da) Fremgangsmåde til bestemmelse af det endogene trombinpotentiale af plasma og blod, samt et kit til anvendelse ved fremgangsmåden
AU751525B2 (en) Method for determining the anticoagulatory potential of a sample
PT984282E (pt) Particulas que tem incorporada uma composicao que compreende um composto quimioluminescente
DE3784589D1 (de) Verwendung von oxidase-enzymsystemen in chemilumineszierenden tests.
DK0690991T3 (da) Ny antikoagulant-cofaktor-aktivitet
CA2002208A1 (en) Extraction methods for preparing thromboplastin reagents
EP1367135A1 (de) Verbessertes Verfahren zur Beurteilung der Thrombinbildung in Blutplasma
DE3473475D1 (en) Process for determining substrate or enzymatic activity
ATE107704T1 (de) Verfahren zur selbstdurchführung von enzymkinetik.
AU6385498A (en) Reagent for determining aptt
US5753510A (en) Calibrator for use in test methods for detecting a defective coagulation factor V
CA2037434A1 (en) Functional assay for determining the protein s activity
ATE208424T1 (de) Verwendung einer vanadin-bromperoxidase als ein signalgenerierendes enzym für chemilumineszierende systeme: testkits und analytische verfahren
ATE274702T1 (de) Verwendung derivatisierter reagenzien in chemilumineszenz- und elektrochemilumineszenz- nachweisverfahren
MY104675A (en) Chromogenic substrate for esterase and immunoassay using same.
DE69928541D1 (de) Luziferase assay, zusammensetzungen und testsätze zu damit in zusammenhang stehenden verwendungen
ES2087892T3 (es) Utilizacion de la superoxido dismutasa en ensayos que implican una oxidasa.
DE69331708T2 (de) Von enzymen katalysierte chemilumineszente detektion von proteinen und nukleinsäuren durch verwendung von hydroxyaryl-cyclischen diacylhydrazid-zusammensetzungen